To evaluate the use of levodopa therapy in patients with Parkinson's disease and malignant melanoma.
DATA SOURCES:
A MEDLINE search (January 1966–September 1999) of English-language articles was conducted. Key search terms included levodopa, melanoma, and Parkinson's disease; 34 case reports were identified.
DATA SYNTHESIS:
Carbidopa/levodopa continues to be a mainstay in the treatment of Parkinson's disease. Since the late 1970s, a warning has appeared in the prescribing literature for levodopa regarding the risk of activating malignant melanoma. An evaluation was conducted of the case reports in which a causal relationship between levodopa and melanoma was suggested.
CONCLUSIONS:
There is an unlikely association between levodopa and induction or exacerbation of malignant melanoma.
SkibbaJLPinckleyJGilbertEFJohnsonRO. Multiple primary melanoma following administration of levodopa. Arch Path1972;93:556–61.
2.
Package insert. Sinemet (carbidopa—levodopa). Wilmington, DE: DuPont Pharmaceuticals, 1998.
3.
JanssonBJankovicJ. Low cancer rates among patients with Parkinson's disease. Ann Neurol1985:17:505–9.
4.
SoberAJWickMM. Levodopa therapy and malignant melanoma. JAMA1978;240:554–5.
5.
BalchCMReintgenDSKirkwoodJMHoughtonAPetersLAngKK. Cutaneous melanoma. In: DevitaVTJrHellmanSRosenbergSA, eds. Cancer — principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven, 1997:1947–94.
6.
MacKieRM. Melanocytic naevi and malignant melanoma. In: ChampionRHBurtonJLBurnsDABreathnachSM, eds. Rook/Wilkinson/ Ebling textbook of dermatology. 6th ed.Oxford: Blackwell Science, 1998:1717–52.
7.
National Parkinson's Foundation, 1999. Available at: www.parkinson.org. Accessed on April 2, 1999.
8.
StandaertDGYoungAB. Treatment of central nervous system degenerative disorders. In: HardmanJGLimbirdLE, eds. Goodman & Gilman's the pharmacological basis of therapeutics. 9th ed.New York: McGraw-Hill, 1996:503–21.
9.
SandykR. Accelerated growth of malignant melanoma by levodopa in Parkinson's disease and role of the pineal gland (letter). Int J Neurosci1992;63:137–40.
10.
BoydAEIIILebovitzHDPfeifferJB. Stimulation of human-growth-hormone secretion by L-dopa. N Engl J Med1970;283:1425–9.
11.
WickMMFitzGeraldGB. Sequential inhibitory effects of quinols– quinones related to levodopa and dopamine upon ribonucleotide reductase and DNA polymerase in vitro (abstract). Proc Am Assoc Cancer Res1984;24:322.
12.
WickMM. L-dopa methyl ester as a new antitumour agent. Nature1977;269:512–3.
13.
BernsteinJEMedenicaMSoltaniKSolomonALorinczAL. Levodopa administration and multiple primary cutaneous melanomas. Arch Dermatol1980;116:1041–4.
14.
WickMM. Therapeutic effect of dopamine infusion on human malignant melanoma. Cancer Treat Rep1982;66:1657–9.
15.
GurneyHCoatesAKeffordR. The use of L-dopa and carbidopa in metastatic malignant melanoma. J Invest Dermatol1991;96:85–7.
16.
RampenFHJ. Levodopa and melanoma: Three cases and review of literature. J Neurol Neurosurg Psychiatry1985;48:585–8.
17.
WarnerTFCSGilbertEFRamirezG. Epidermotropism in melanoma. J Cutan Pathol1980;7:50–4.
18.
RobinsonEWajsbortJHirshowitzB. Levodopa and malignant melanoma (letter). Arch Pathol1973;95:213.
19.
LiebermanANShupackJL. Levodopa and melanoma. Neurology1974;24:340–3.
20.
FermaglichJDelaneyP. Parkinson's disease, melanoma, and levodopa. J Neurol1977;215:221–4.
21.
FermaglichJ. Melanoma and Parkinson's disease (abstract). Neurology1978;28:404.
22.
Van RensGHDeJongPTVMDemolsEEJLRGeertruydenMF Brihaye-VanUveal malignant melanoma and levodopa therapy in Parkinson's disease. Ophthalmology1982;89:1464–6.
23.
AbramsonDHRubenfeldMR. Choroidal melanoma and levodopa (letter). JAMA1984;252:1011–2.
24.
RosinMABraunMIIIMalignant melanoma and levodopa. Cutis1984;33:572–4.
25.
PrzybillaBSchwabULandthalerMBruan-FalcoO. Development of two malignant melanomas during administration of levodopa. Acta Derm Venereol (Stockh)1985;65:556–7.
26.
KocharAS. Development of malignant melanoma after levodopa therapy for Parkinson's disease. Report of a case and review of the literature. Am J Med1985;79:119–21.
27.
HaiderSAThallerVT. Lid melanoma and parkinsonism. Br J Ophthalmol1992;76:246–7.
28.
WoofterMJAManyamBV. Safety of long-term levodopa therapy in malignant melanoma. Clin Neuropharmacol1994;14:315–9.
29.
PfutznerWPrzybillaB. Malignant melanoma and levodopa: Is there a relationship? Two new cases and a review of the literature. J Am Acad Dermatol1997;37:332–6.
30.
WeinerWJSingerCSanchez-RamosJRGoldenbergJN. Levodopa, melanoma, and Parkinson's disease. Neurology1993;43:674–7.
31.
MerelloMEsteguyMPerazzoFLeiguardaR. Impaired levodopa response in Parkinson's disease during melanoma therapy. Clin Neuropharmacol1992;15:69–74.
